MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.01
-0.06
-0.26%
Opening 12:31 05/24 EDT
OPEN
22.82
PREV CLOSE
23.07
HIGH
23.21
LOW
22.45
VOLUME
133.71K
TURNOVER
2.04M
52 WEEK HIGH
31.65
52 WEEK LOW
12.75
MARKET CAP
1.46B
P/E (TTM)
-7.0361
1D
5D
1M
3M
1Y
5Y
Former pharmaceutical exec Martin Shkreli released from prison
reuters.com · 5d ago
Travere Therapeutics Announces Presentations Of Abstracts At The 59th ERA Congress
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy
Benzinga · 6d ago
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA neph...
GlobeNewswire · 6d ago
Analyst Ratings for Travere Therapeutics
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:
Benzinga · 6d ago
HC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here's What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Travere Therapeutics (NASDAQ:TVTX) and raise its price target from $45.00 to $46.00. Shares of Travere Therapeutics are trading up 8.5% over the last 24 hours, at $25.54 per share.
Benzinga · 05/17 16:01
HC Wainwright Adjusts Travere Therapeutics' Price Target to $46 From $45, Reiterates Buy Rating
MT Newswires · 05/17 07:53
Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug
The FDA accepted Travere Therapeutics' application for a kidney disease treatment on Monday, leading TVTX stock to surge higher.
Investor's Business Daily · 05/16 16:28
FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review
The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of IgA nephropathy (IgAN).
Benzinga · 05/16 14:38
More
No Data
Learn about the latest financial forecast of TVTX. Analyze the recent business situations of Travere Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
40.00%Buy
10.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TVTX stock price target is 40.56 with a high estimate of 49.00 and a low estimate of 24.00.
High49.00
Average40.56
Low24.00
Current 23.01
EPS
Actual
Estimate
-0.96-0.72-0.48-0.24
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 235
Institutional Holdings: 69.08M
% Owned: 108.77%
Shares Outstanding: 63.51M
TypeInstitutionsShares
Increased
50
5.48M
New
40
4.60M
Decreased
50
3.73M
Sold Out
16
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.06%
Pharmaceuticals & Medical Research
-0.18%
Key Executives
Non-Executive Chairman/Independent Director
Gary Lyons
President/Chief Executive Officer/Director
Eric Dube
Chief Financial Officer
Laura Clague
Senior Vice President/General Counsel/Secretary
Elizabeth Reed
Senior Vice President
William Rote
Chief Accounting Officer/Vice President/Controller
Sandra Calvin
Other
Peter Heerma
Other
Jula Inrig
Independent Director
Roy Baynes
Independent Director
Suzanne Bruhn
Independent Director
Timothy Coughlin
Independent Director
Jeffrey Meckler
Independent Director
John Orwin
Independent Director
Sandra Poole
Independent Director
Ron Squarer
Independent Director
Ruth Williams-Brinkley
No Data
No Data
About TVTX
Travere Therapeutics, Inc. (Travere) is an integrated biopharmaceutical company that is focused on identifying, developing and delivering therapies to people with rare diseases. Travere’s products include Chenodal (chenodiol tablets), holbam (cholic acid capsules), and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker (ARB).

Webull offers kinds of Travere Therapeutics Inc stock information, including NASDAQ:TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.